WeVote
Log In

Bill

Bill

SB 1542

controlled substances; approval; use; research

57th Legislature - Second Regular Session Introduced by Kevin Payne

Arizona bill authorizes state-approved research on controlled substances, potentially enabling psychedelic/MDMA studies while creating federal-state legal tensions.

Senate Second Reading
0
WeVote Research Nonpartisan
Bill Summary · SB 1542

Legislative bill overview

SB 1542 proposes to establish a framework for approving controlled substances for medical research purposes in Arizona. The bill would create a regulatory pathway allowing qualified researchers to conduct studies on Schedule I and II controlled substances under state oversight. This addresses the current disconnect between federal restrictions and growing scientific interest in substances like psilocybin and MDMA for therapeutic applications.

Why is this important

Arizona could position itself as a research hub for emerging psychopharmacology while potentially developing evidence-based treatments for conditions like PTSD, depression, and cluster headaches. The outcomes could influence both state medical practice and contribute to national conversations about drug scheduling and research access. However, this also creates tension between state and federal law, since Schedule I substances remain federally prohibited for most research purposes.

Potential points of contention

  • Federal-state legal conflict: State approval doesn't override federal DEA restrictions, creating legal ambiguity for researchers and institutions that receive federal funding
  • Public safety concerns: Opponents may argue that state-level approval of controlled substance research normalizes drug use or creates regulatory loopholes
  • Implementation details: The bill's current stage suggests the approval criteria, researcher qualifications, and oversight mechanisms remain undefined and could face significant debate

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.